Rain Therapeutics RAIN 深 沪
等待开盘 12-17 09:30:00 美东时间
5.92
-0.120
-1.99%
华盛通- 最 高6.24
- 今 开5.88
- 成交量 2.03万股
- 最 低 5.7393
- 昨 收 6.04
- 总市值 4847.77万
- 52周最高 10.84
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.21
- 委 比 -38.46%
- 总股本 818.88万
- 历史最高 23.90
- 量 比 0.74
- 振 幅 8.29%
- 历史最低 0.82
- 每 手 1
- 风险率 1.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Industrials Stocks Moving In Tuesday's Pre-Market Session
Gainers FGI Industries (NASDAQ:FGI) stock increased by 16.4% to $6.26 during T...
12-16 20:05
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Shares of B Riley Financial Inc (NASDAQ:RILY) rose sharply in pre-market tradin...
12-16 18:53
Rain Enhancement Tech Stock Jumps On Colorado Rain System Debut
RAIN jumps ~15% as Colorado's first warm-weather ionized rainfall system goes live in Gill under permit through Oct. 31, 2026.
11-12 00:17
Rain Enhancement's WETA Ionization Technology Begins Operations Of First U.S. Installation Following Approval Of Weather Modification Permit From State Of Colorado's Water Conservation Board
Company's WETA Ionization Technology Begins Operations in Gill, Colorado, Marking State's First Warm Weather Modification ProgramNAPLES, FL / ACCESS Newswire / November 11, 2025 / Rain Enhancement Technologies Holdco,
11-11 22:13
12 Industrials Stocks Moving In Tuesday's Pre-Market Session
Gainers Cycurion (NASDAQ:CYCU) stock increased by 28.4% to $3.39 during Tuesda...
11-11 20:07
12 Industrials Stocks Moving In Friday's After-Market Session
Gainers The Generation Essentials (NYSE:TGE) stock moved upwards by 35.0% to $...
11-01 05:07
GRAINGER DECLARES QUARTERLY DIVIDEND
CHICAGO, Oct. 29, 2025 /PRNewswire/ -- W.W. Grainger, Inc. (NYSE: GWW) today announced its board of directors has approved a quarterly cash dividend of $2.26 per share. The dividend is payab...
10-29 22:17
Insights into Impinj's Upcoming Earnings
Impinj (NASDAQ:PI) will release its quarterly earnings report on Wednesday, 202...
10-29 03:01
Why Is Genmab Stock Trading Lower On Monday?
Genmab reported a 50% response rate and durable results for Rina-S in advanced endometrial cancer, with manageable side effects and no major toxicities.
10-20 23:57
Reported Saturday, Genmab's Rinatabart Sesutecan Achieves 50% Objective Response Rate And Two Complete Responses In Advanced Endometrial Cancer; Phase 3 Trial And US FDA Breakthrough Therapy Designation Underway
Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of
10-20 16:08
